Using mitochondrial DNA as a biosensor of early cancer development by Birch-Machin, M A
Editorial




1Dermatological Sciences, Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
British Journal of Cancer (2005) 93, 271–272. doi:10.1038/sj.bjc.6602711 www.bjcancer.com
& 2005 Cancer Research UK
              
Mitochondria can perform multiple cellular functions including
energy production, cell proliferation and apoptosis. Each
human cell contains hundreds to several thousand copies of
the 16.5kb human mitochondrial genome, which incidentally
exhibits a maternal pattern of inheritance. This closed circular
genome encodes 13 polypeptides of the respiratory chain
complexes, as well as 22 transfer RNAs and two ribosomal RNAs
used in mitochondrial protein synthesis. Compared to nuclear
DNA, mitochondrial DNA (mtDNA) is highly susceptible to
damage because it is not associated with protective histones, it is
continually exposed to high levels of reactive oxygen species (ROS)
generated by oxidative phosphorylation, and there is a limited
capacity for mtDNA repair. The complete mtDNA sequence was
determined in 1981 and resequenced in 1999. A growing collection
of reported mtDNA mutations and rearrangements has
been associated with muscle and neurodegenerative diseases
(Birch-Machin, 2000).
MTDNA DAMAGE AND CANCER
Mitochondria have been implicated in the carcinogenic
process because of their role in apoptosis and other aspects
of tumour biology. In particular, study of mtDNA mutations
in cancer is a rapidly expanding area that explores the links
of neoplastic growth with DNA modifications within this
organelle. Many types of human malignancy such as colo-
rectal, liver, breast, lung, prostate, skin and bladder cancer
have been shown to harbour somatic mtDNA mutations (Copeland
et al, 2002; Durham et al, 2003; Petros et al, 2005). In this issue
of the BJC, Nishikawa and colleagues from Hyogo Medical
School, Japan, present their findings that indicate accumulation
of mtDNA mutations with colorectal carcinogenesis in ulcerative
colitis (UC). In addition, the levels of 8-OHdG, a DNA
adduct produced by ROS were significantly higher in UC than
in control. Taking both observations together, the authors
postulate the interesting idea that the high incidence of mtDNA
mutations is enhanced in the mucosal cells of the patients with UC
by a process of oxidative stress caused by the chronic inflamma-
tion. This in turn means that malignant transformation occurs
more easily than in normal subjects. There are a number of
important aspects surrounding this article some of which deserve
wider reflection.
MTDNA AS A SENSITIVE BIOSENSOR OF GENETIC
DAMAGE
There are many mitochondrial genomes (2–10 copies) per
mitochondria and many mitochondria per cell (a mammalian cell
typically contains 200–2000 mitochondria). As a consequence,
therefore, mitochondrial genomes can tolerate very high levels
(up to 90%) of damaged DNA through complementation by the
remaining wild type. This fact coupled with the limited DNA repair
capacity of mtDNA can lead to the accumulation of genetic damage
without compromising cell function, that is, two factors which are
necessary requirements for a reliable and sensitive biosensor.
ROS IN CANCER CELLS
Growing evidence suggests that cancer cells exhibit increased
intrinsic ROS stress, due, in part, to oncogenic stimulation,
increased metabolic activity and mitochondrial malfunction. Since
the mitochondrial respiratory chain is a major source of ROS
generation in the cells and the naked mtDNA molecule is in close
proximity to the source of ROS, the vulnerability of the mtDNA to
ROS-mediated damage appears to be a mechanism to amplify ROS
stressing cancer cells (Pelicano et al, 2004).
PROTEOMIC ANALYSIS OF CANCER-CELL
MITOCHONDRIA
Despite the increased identification of signatures of mtDNA
damage in transformed cells, the phenotypic effects of these
genetic changes remain to be established. Research into the
identification of altered expression patterns of mitochondrial
proteins in cancer cells has been made possible by the relatively
recent development of mitochondrial functional proteomics. The
potential of this field may be realized in the identification of new
markers and risk assessment as well as therapeutic targets.
However, proteomic analyses face more challenges than the
genomic approach. For example, the behaviour of proteins is
largely determined by the tertiary structure of the molecule which
puts constraints on affinity-based assays to capture protein targets.
In addition, many proteins exist at very low levels, which in the
absence of an amplification system equivalent to the polymerase
chain reaction for DNA would make them difficult to identify and
subsequently analyse. Finally, protein function is not necessarily
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degradation, reversible modification and RNA splicing (Verma
et al, 2003).
FUTURE APPROACHES
Despite the difficulties with mitochondrial proteomics, it is likely
that the combination of the mitochondrial genetic and the
proteomic approaches will provide an effective double edge sword
in the fight against cancer. It is hoped that this strategy will
provide specific genetic markers and protein profiles which
will provide early detection, risk assessment and new targets for
treatment. It may also help to answer the much debated question
as to whether the observed mtDNA damage has a primary and
causative link to the process of cancer development or it may
simply represent a secondary bystander effect, which reflects an
underlying nuclear DNA instability. One cautionary note in all
these studies is the use of appropriate control tissue for cancer
studies. This is highlighted by the work of Durham et al., who
found that the traditional use of histologically ‘normal’ perilesional
skin in nonmelanoma skin cancer studies had several limitations
since the ‘normal tissue’ also harbored UV-induced mtDNA
damage. These results may suggest, however, that neoplasia is
evident at the molecular level before pathohistological changes are
visible, a feature which itself may provide a powerful biosensor of
early cancer development.
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